• Company will seek approval for name change at Annual General Meeting scheduled for May 10, 2021
• Name change symbolizes company’s resurgence as relevant contender in U.S. cannabis industry.
• Company currently operates seven Chalice Farms dispensaries throughout the Portland area.

Golden Leaf Holdings (CSE: GLH) (OTCQB: GLDFF), a proven, consumer-driven cannabis company in both the medicinal and recreational marijuana market segments, is planning to make an official corporate name change (https://ibn.fm/gVGzW). The company announced that it will be changing its name to Chalice Brands Ltd. at its annual and special meeting (“AGM”), which is slated for May 10, 2021. “With the hard work of the turnaround behind us, we continue to gather momentum and galvanize management behind the Chalice brand,” stated CEO Jeff Yapp. “Our Chalice Farms stores and our Chalice chews are the pride of our business. As we put the Golden Leaf era behind us, this name change serves to symbolize our resurgence as a relevant contender in the U.S. cannabis industry, driven by leadership in our home market of Oregon.” There are currently seven Chalice Farms dispensaries throughout the Portland area. The open, inviting locations are recognized for the enjoyable consumer experience they offer as GLF has focused on creating a welcoming atmosphere, a wide array of compelling products and an invaluable resource for its customers, regardless of their product experience. In addition to offering some of the highest-quality products from third-party companies, Chalice Farms has its own product line: Chalice Chews. This nutritionally enhanced and award-winning fruit edibles line offers a wide range of flavors, from CBD Green Apple, Kiwi Strawberry and Lemon Ginger to Tangerine, Tropical and Acai Berry. Chalice Chews are an ideal option because they offer a wide range of options, including formulations designed to help support the body and mind, recover from a workout, enjoy a natural energetic zip or slide gently into a great night’s sleep (https://ibn.fm/6y2Wo). In addition to obtaining approval for the name change at the next AGM, company officials plan to seek approval for a share consolidation with the objective of bringing outstanding common shares to approximately 65 million. Details of agenda items for the meeting will be included in the management information circular mailed later this month. Company officials have noted that the name change and share consolidation are both expected to receive overwhelming support. For more information, visit the company’s website at www.GoldenLeafHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to GLDFF are available in the company’s newsroom at https://ibn.fm/GLDFF

• 90% of the cystoscopies performed on bladder cancer patients use white light, which cannot always detect cancer margins or tumors that lie flat against the bladder wall. The American Urology Association recommends blue light for cystoscopic procedures involving bladder cancer.
• Imagin Medical’s i/Blue Imaging System(TM) provides the simultaneous, side-by-side display of white light and blue light images, making it easier to visualize cancer margins and flat tumors, potentially resulting in lower recurrence rates
• The company is has transitioned to the manufacturing stage of the i/Blue System with their contract manufacturer, Lighthouse Imaging
• Bladder cancer is the sixth most prevalent cancer in the United States, with approximately 81,400 new cases in 2020 and approximately 17,980 deaths in 2020

Surgical imaging company, Imagin Medical (CSE: IME) (OTCQB: IMEXF), is on the innovative edge of visualizing bladder cancer, aiming to overcome the challenges associated with current imaging techniques. The conventional treatment for bladder cancer is white light cystoscopy that allows doctors to insert a cystoscope equipped with a lens through the urethra to illuminate and examine the outer wall of the bladder. Cystoscopies may be performed for the following reasons:

• Investigation of signs and symptoms of blood in the urine, incontinence, overactive bladder, and painful urination
• Diagnosis of bladder diseases and conditions, s including bladder cancer, bladder stones, and inflammation within the bladder
• Treatment for bladder diseases and conditions when Special tools can pass through the cystoscope to treat specific conditions and/or remove tumors

Even though the American Urology Association recommends using blue light for cystoscopies, 90% are still performed with white light which cannot clearly visualize the margins of tumors that protrude above the bladder wall or those that run flush along the surface. With the use of a contrast agent that causes cancerous growths to fluoresce, blue light cystoscopy enables surgeons to better visualize the margins of tumors above the wall as well as the flat cancerous growths on the surface, In addition, this method has been proven to reduce bladder cancer recurrence. Two downsides to blue light cystoscopy are its steep price tag and the way that the highlighted blue images displayed on the monitor are not in real time, requiring surgeons to manually switch back and forth between the white and blue light images and rely on memory to resect the cancer. In addition, the current method requires hospitals to purchase proprietary endoscopes, rather than use the standard scopes they already own. Imagin Medical’s innovative i/Blue Imaging System combines blue light and the same already FDA approved contrast agent with advanced optics and light sensors, and employs patented ultrasensitive imaging technology to address these limitations. Both white light and blue light images will be in real time and can be displayed side-by-side on the same monitor, eliminating the need to switch back and forth and providing surgeons with more accurate visualization to resect. Additionally, the i/Blue Imaging System can be adapted to most endoscopes on the market, making it unnecessary for hospitals to swap out their equipment, which makes for a highly cost-effective approach. The company has entered the manufacturing stage with FDA-registered contract manufacturer, Lighthouse Imaging. Imagin Medical intends to expand its technology to other procedures in the future, but the primary focus for now is on bladder cancer, the most expensive form of cancer to treat over the lifetime of a patient. According to Verified Market Research, the global bladder cancer market was valued at $3.43 billion in 2018 but is projected to grow at a CAGR of 4.03% and reach $4.71 billion by 2026 (https://ibn.fm/LfWJx). Bladder cancer is the sixth most prevalent cancer in the United States, totaling 81,400 new cases in 2020 and resulting in approximately 17,980 deaths in 2020. Imagin Medical believes its technology has the potential to revolutionize the current standard of care for bladder cancer patients by advancing the efficiency and accuracy of cancer detection and removal, and potentially reducing recurrence rates. For more information, visit the company’s website at www.ImaginMedical.com. NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• DGTL Holdings Inc. subsidiary signed a multiyear software licensing agreement with a digital sports entertainment and gaming giant
• The first marketing campaign focused on the client’s premier sports gaming brands targeting the 2021 NCAA Men’s Basketball Championship that commenced March 2021.
• Based on the success of this campaign, DGTL was awarded a second activation just one week later for a major league sports activation with the PGA Masters
• DGTL recorded $1,253,000 in revenue for the three months ending November 30, 2020 and sales have grown an average of +75% YOY in the last two quarters

DGTL Holdings (TSX.V: DGTL) (OTCQB: DGTHF) is focused on building a full-service digital media, marketing, and advertising software platform powered by Artificial Intelligence (“AI”) for growth-stage digital media, marketing, and advertising software technology companies. Their goal is to build a portfolio of content, measurement and distribution-based software technologies in the high growth categories social media, gaming, streaming and web advertising. The company recently reported that its wholly-owned subsidiary, Hashoff LLC, has signed a new campaign activation contract with the leading digital sports entertainment and gaming technology company. The client is a top sponsor for a numerous major league sports organizations including; the NBA, NFL, PGA, MLB, NHL and NCAA as well as Nascar, UFC, etc. This client joins a list of global brand juggernaut customers, including Amheuser Busch, Dunkin Brands, Syneos Health, Dentsu, Publicis, Shein, and many others. With these first two major activations, this SaaS licensing agreement includes additional social media marketing strategies for other major sporting events during the two-year term. The first campaign focused on the client’s premier sports gaming brands at the 2021 NCAA Men’s Basketball Championship – “March Madness”, which runs from March 14 to April 5, 2021. The client will leverage Hashoff’s video-based social media content management software to source and manage the top sports agencies, with the goal of driving greater online traffic and engagement on their sports gaming applications. Based on the successful completion of this campaign, the client awarded a contract to cover their brand at the PGA Masters tournament beginning on April 8th, 2021. The Nasdaq listed client, with a market value of over $25 billion, is a global leader in developing and marketing fantasy sports and mobile sports betting applications that enable users to bet on sports-related contests, tournaments, or fantasy sports leagues (https://ibn.fm/IkcPS). Earlier, DGTL Holdings Inc. announced its financial results for the three and six-month periods ending November 30, 2020, representing Q2 and YTD results for FYE 2021.

• DGTL recorded $1,253,000 in revenue for the three months ending November 30, 2020.
• Hashoff recorded a 70% growth in revenue at $738,000 for the same quarter in 2019.
• Compared to DGTL’s revenue of $1,352,000 for the semi-annual period in 2019, the company recorded $2,416,000 for the six months ending November 30, 2020, representing a 79% growth in revenue.
• DGTL Current 2020 calendar year revenue through November 30, 2020, is $3,740,000, compared to $2,320,000 during the same period in 2019, showcasing a growth rate of 61%.

The company attributes the revenue growth to the implementation of DGTL’s three-year revenue growth plan and Hashoff’s exemplary services. Hashoff is fast gaining ground as a leading social media CMS with the surging market demand for CaaS (content-as-a-service) platforms (https://ibn.fm/BL66p). For a multimedia video on Hashoff’s platform at https://ibn.fm/qbHIC For more information, visit the company’s website at www.DGTLInc.com. NOTE TO INVESTORS: The latest news and updates relating to DGTHF are available in the company’s newsroom at https://ibn.fm/DGTHF

• Splash board members boast diverse, extensive leadership experiences in array of industries.
• Board members have served for decades in key roles related to successful growth of Splash.
• Splash Beverages operates in both alcoholic, nonalcoholic beverage segments.

The impact leaders have on organizations is almost impossible to measure — yet they are critical components of a company’s success. Splash Beverage Group (OTCQB: SBEV), a holding company of leading portfolio of beverage brands, blend of essential vitamins, minerals and electrolytes, is committed to building a leadership team — including stellar board members — with the expertise and insight necessary for the company’s growth in the trillion-dollar global beverage industry. Most recently, Splash Beverage announced the appointment of Peter McDonough as an independent board member (https://ibn.fm/2EZXw). McDonough has an unparalleled C.V. for sitting on the board of an upstart company, and he brings incomparable marketing experience to Splash, the company noted, when making the announcement. “We are lucky to be adding Peter to our board,” said Splash Beverage CEO Robert Nistico. “Over the course of his 30-year career, Peter has created successful marketing campaigns and built organizational capabilities that accelerated the growth of business enterprises ranging from small start-ups as well as multi-billion-dollar companies. Peter’s wealth of experience and insights gained while serving as Diageo’s North American president overseeing brand marketing and product development, as well as his vast professional network will be invaluable to Splash’s board of directors. His strategic insights offer helpful counsel as Splash accelerates the growth of our existing brands, TapouT Beverage and Salt Tequila, while adding new brands and expanding our distribution footprint into international markets.” McDonough has garnered diverse and deep leadership experiences in industries such as personal care products, alcoholic beverages, consumer appliances, power tools and bioscience technology. He currently serves as CEO of Trait Biosciences and previously served in senior executive roles at Diageo, Procter & Gamble, Gillette, Duracell and Black & Decker. At Diageo, McDonough acted as president as well as chief marketing & innovation officer. Under his expert guidance, the company launched more than 40 new products in less than a decade, resulting in more than $800 million in cumulative sales and the company’s consistent appearance in the industry’s annual (IRI/Nielsen) list of top-selling new products. Other outstanding Splash Beverage board members include Nistico, who is a board member in addition to serving as Chairman & CEO; and Justin Yorke. Boasting almost three decades of experience in the beverage industry, Nistico was named Splash CEO and a member of the board of directors since inception. Prior to that, he served as Senior Vice President and general manager at Red Bull North America, where he was the fifth employee hired. Nistico was instrumental in building the Red Bull brand in North and Central America as well as the Caribbean. He’s also held key leadership positions at Diageo (formerly I.D.V./Heublein), Republic National (formerly the Julius Schepps Company) and the E&J Gallo Winery. Yorke is a member of the board of directors and, in March of last year, was also named secretary for the company. With more than two decades of experience in finance — including almost half of that in Hong Kong — Yorke has managed funds for a private Swiss bank as well Peregrine Investments and Unifund, a high-net-worth family based in Switzerland. For the past ten years, Yorke has been a partner in San Gabriel Advisors and is the manager of the San Gabriel Fund, JMW Fund and Richland Fund. Specializing in manufacturing, distributing, sales and marketing of various beverages across multiple channels, Splash Beverages operates in both the alcoholic and nonalcoholic beverage segments, allowing it to leverage efficiencies and dilute risk. The company’s business strategy is to quickly develop and accelerate pre-existing brands to exit for cash events. The company’s management team has invaluable expertise and insight, and the company strives to identify brands it perceives to have highly visible preexisting brand awareness or pure category innovation. Specifically, the company looks for brands and products that are on trend and deliver natural quality, health benefits, freshness and refreshment within their beverages. SBEV looks to maintain highest performance standards and focus on execution as it works with distributors and retail partners achieve and exceed all goals. In addition, the company offers support for members of the U.S. armed forces, first responders and health-care professionals. For more information, visit the company’s website at www.SplashBeverageGroup.com. NOTE TO INVESTORS: The latest news and updates relating to SBEV are available in the company’s newsroom at https://ibn.fm/SBEV

• The novel coronavirus has spawned a number of health-preserving policies, including growing use of remote workplace models to keep employees from close contact with each other
• Lone workers without the immediate physical support of their colleagues may face heightened vulnerability to outside threats, however
• Company facilities may also face heightened vulnerability because of skeleton crew reductions
• Autonomous security robots (“ASRs”) such as those developed by Knightscope can help reduce vulnerabilities through property patrols at the workplace and in public places ranging from parks to parking garages

Autonomous security robot (“ASR”) visionaries at Knightscope are advancing their mission to “make the United States of America the safest country in the world” by producing solutions that don’t sleep, don’t fall ill during a pandemic, and don’t succumb to performance-inhibiting factors such as boredom when things appear to be relatively quiet. Knightscope’s ASR sentries are a friendly, weaponless presence serving clients ranging from the private sector to federal government, proving its use not through interdiction but through detection and allowing its human security partners to determine where to take things from there. The ASRs’ detection capabilities cover a wide range of potential — monitoring signal transmissions that might communicate the launch of a physical threat, heat sources that might indicate a fire still in embryo, human presences that are unexpected or unauthorized, and specific identification features that might be used as clues to solve criminal cases, for example. The Las Vegas Review-Journal recently reported the company’s success in serving a metropolitan apartment complex with a history of significant criminal activity, noting that the complex has become “a quieter, more peaceful place to live” since a Knightscope ASR was deployed there last fall and helped reduce the incidence of crime and vandalism (https://ibn.fm/oCj0D). Security concerns are as pressing as ever in the era of the COVID pandemic, when companies are relying heavily on distributed workforce models that help employees maintain their health and wellbeing by working from a remote base outside the office. Trade magazine Security recently observed that the pandemic has created more “lone workers” than ever, defined as “individuals who work alone without close or direct supervision, and are often more vulnerable to risks that many office-based workers may not experience.” The magazine commented that, “Organizations in charge of protecting lone workers must fulfill their duty of care, taking all steps reasonably possible to ensure the safety, well-being and physical and mental health of their employees,” with the consequence of inaction being that critical employees may become vulnerable to harm and leave the company itself vulnerable to harm as well (https://ibn.fm/HRREQ). Those vulnerabilities can occur at the remote locations, where workers may find themselves exposed to dangerous influences without having other supportive staffers nearby to provide help, or at the company’s physical facilities, where a skeleton crew of employees may be unable to sufficiently respond to an attack on the business’s infrastructure, Security states. Understaffed security forces have “been forced into lone worker scenarios and are suffering from a lack of support resources. They cannot just watch people as they used to, as they’re tasked to do an impossible job of dealing with guest requests, front desk work by checking people in and out, while still responsible for overseeing perimeter security and the monitoring of visitors,” Karl Perman, president and co-founder of risk consultancy CIP CORE, told the magazine. Perman suggested that organizations can’t afford to operate under the same security program that existed before the COVID-19 outbreak. One potential solution is Knightscope’s range of autonomous robot sentries, which currently have been deployed in three types of models — one that is stationary within the office complex, one equipped to rove the office building with obstacle avoidance a part of its basic programming, and a third that is capable of patrolling the property outside the office complex. “A violent crime occurs every four seconds and a property crime every 25 seconds. … Crime has more than a trillion-dollar negative economic impact on the U.S. every single year,” Knightscope founder and CEO William Santana Li says in a recent YouTube video about him and the company (https://ibn.fm/QiMpO), adding in another video, “Each (Knightscope robot) proudly displays the stars and stripes, signifying our patriotic duty to our country” (https://ibn.fm/oNWic). Knightscope has exceeded 20,000 investors since rolling out its first autonomous product in 2015, utilizing a Reg A+ offering that allows Knightscope to attract private investments without establishing a public IPO (https://ibn.fm/kzbP9). For more information, visit the company’s website at www.Knightscope.com. Visit www.Knightscope.com/invest for a summary of Knightscope as an investment, with a blue Instant Messaging button for direct contact with their CEO. DISCLAIMER: You should read the Offering Circular and risks related to this offering before investing. This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/Knight

• Cybin has completed more than 20 pre-clinical studies in record time.
• Company is advancing two new therapeutic candidates with enhanced, improved properties.
• Drug candidates are designed to treat serious psychiatric conditions with high unmet medical needs.

Cybin (NEO: CYBN) (OTCQB: CLXPF), a leading biotech company focused on progressing psychedelic therapeutics, has completed key research studies both in vitro and in vivo. The company recently announced that it had completed its 20th pre-clinical study and had progressed two psychedelic investigational new drug candidates: CYB003 and CYB004 (https://ibn.fm/jDvFz). The studies were completed in record time, the company reported, in part because of close collaboration with its partners and contractors. “Excellent teamwork and fully supportive partners have greatly facilitated the advancement of these two new therapeutic candidates with enhanced and improved properties,” said Cybin chief R&D officer Michael Palfreyman. “We look forward to rapid progress towards clinical studies.” The completed studies were focused on evaluating proprietary Cybin technologies, and more than 20 definitive research studies designed by the Cybin scientists were conducted. Results of the studies have led to the progression CYB003 and CYB004, two proprietary psychedelic therapeutics which have entered into full IND-enabling studies. These studies are in preparation for upcoming clinical testing designed to analyze the effectiveness of these therapeutics in the treatment of serious psychiatric conditions with high unmet medical needs. The company has also initiated an API manufacturing contract with a strategic pharmaceutical manufacturing partner. According to Cybin, the pre-clinical studies of CYB003 and CYB004 candidates included API synthesis and optimization to prove that the two psychedelic molecules show significant in vivo modifications of pharmacokinetics consistent with proof of concept. These two studies are only a part of Cybin’s impressive pipeline. Currently the company is developing more than 50 proprietary psychedelic molecules and multiple proprietary delivery mechanisms and supportive technology platforms. The company plans to continue to progress its novel next-generation psychedelics based on well-known scaffolds including psilocybin, DMT, MDMA with improved bioavailability and optimized pharmacokinetic profiles to provide shorter duration of action with the potential for reduced side effects. “Our internal research and development team, along with an extensive network of partners, has progressed CYB003 and CYB004 into IND-enabling studies at an impressive pace,” said Cybin CEO Doug Drysdale. “I am in no doubt we have the best team in this sector and the right team to progress these exciting future treatments into clinical studies over the next 12 months.” Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug- discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Healthy Extracts Inc. recently declared its 2020 Q4 results, with revenue growth at 71% over the previous year
• The company’s 2021 strategy “Live Life Young Again” aligns with its plant-based product range and its overall confidence for 2021
• Results of the clinical studies of the Fuel4Thought Brain Booster product were published in the renowned World Journal of Advanced Research and Reviews

Healthy Extracts (OTCQB: HYEX), is engaged in the research, development, and sale of natural plant-based products that concentrate on nerve and heart health. The company’s growth and expansion are evident in the company’s robust 2020 Q4 results. Their latest financial report highlights the revenue increase of 71% at $1,276,559 compared to 2019 revenues of $748,377. The plant-based food industry is expected to reach a value of $74.2 billion in 2027, guided by a CAGR of 11.9% from 2020 to 2027 (https://ibn.fm/HrwvF). Duke Pitts, president of Healthy Extracts Inc., stated that the 2020 results reflected the upward momentum of the company. The company recently changed its name from Grey Cloak Tech Inc. to Healthy Extracts, Inc., better aligned with the company’s objectives. Healthy Extracts is geared towards 2021 with its “Live Life Young Again” strategy. Some key highlights of 2020 include:

• Gross revenue recording an increase of 71% in 2020, despite the COVID situation
• Healthy Extracts Inc. (HYEX) name change from Grey Cloak Tech with full reporting and move up to the OTCQB
• The company’s elimination of all convertible debt
• Net shareholder equity increase of $3.7 million
• Collaboration with Ultimate Brain Nutrients, a science-based company that has six patents (2 issued, 4 pending) and proprietary formulations
• Introduction of Clinical Immune, a clinically proven immunity product focusing on heart and respiratory immune health
• Sales of Fuel4Thought Brain Booster product to begin in Q2 after completion of key clinical studies
• Launch of HerHeart, the only cardiovascular product for women, with positive clinical trial results published in Annals of Women’s Health (https://ibn.fm/DVasH)

The company is making remarkable strides to strengthen its market positions in the plant-based health industry through its two key subsidiaries, the science-based BergaMet North America and Ultimate Brain Nutrients (“UBN”). For more information, visit the company’s website at www.HealthyExtractsInc.com. NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

• With pandemic-imposed restrictions in place, more artists and fans turn towards livestreaming options such as Fan Pass
• Providing a safe option for engagement, interaction and additional revenue for artists, Fan Pass has been growing exponentially since its launch in July 2020
• Platform offers an additional incentive for artists in the form of monthly contests resulting in higher streaming rates and sign-ups

Mobile technology and marketing company Friendable (OTC: FDBL) is continuing to engage users and provide an online stage for artists who want to connect with their fans through the Fan Pass platform, paving the way for other virtual venues in a year that will likely continue without major in-person events as a result of the pandemic and social distancing norms. Even though larger venues were hoping to open their doors (or lawns) to large-scale events in 2021, it isn’t looking like that will be an option, except for some late fall shows. Even then, those dates are tentative. South by Southwest has already decided on a completely virtual event this year. Coachella and Stagecoach, two of the largest California festivals, have been canceled for a second year. Most musical artists are changing their tour dates to begin in 2022, according to a USA Today report (https://ibn.fm/c1xD4). Experts in the industry say that even if the smaller venues bring in local artists, not to expect much in terms of “meet and greet” due to the COVID restrictions in place. “Besides being smaller with a lower capacity, there will undoubtedly be mask requirements and restrictions on some of the things we are used to – less food, more restrictions on drinking and more efforts to keep people from congregating too closely. Don’t expect any meet-and-greets with artists or any stage dives by the lead singer,” senior correspondent for Billboard, Dave Brooks, said. While restrictions remain in place, artists and fans have turned towards livestreaming alternatives such as Friendable’s Fan Pass platform. Since its launch in July 2020 at the height of the pandemic, Fan Pass has seen remarkable growth as a virtual venue that allows artists and fans to interact safely and maintain engagement while providing artists with revenue-genera ting opportunities and fans with valuable content from the artists they admire. As an added incentive for artists, Fan Pass holds monthly contests offering prizes or cash for most event views. The March prizes and winners include:

1. First Place – Ball Hog Beats: GoPro HERO9 or $300 cash
2. Second Place – Yungblaze619: Streaming Kit ($250 value) or $150 cash
3. Third Place – Cartier Icon: Custom Design ($100 value) or $50 cash

The April contest is now underway and offers every artist who schedules and completes their first livestream event on the platform a $25 incentive. The prizes for April have changed from those in the previous months. The GoPro HERO9 has been replaced with a higher valued prize for the month of April. Fan Pass urges artists to schedule their events early to get ahead in the contest. One of the first artists to schedule an event for April is K. Burns – holding his first livestream event on the platform on April 5. The April contest offers artists:

1. First Place: Streaming Kit ($450 value) or $350 cash
2. Second Place: Merch Collection ($300 value) or $200 cash
3. Third Place: Custom Design ($100 value) or $50 cash

Fans can watch the artists’ streaming event if they are subscribers or for additional ticket pricing. To subscribe to the Fan Pass “Virtual Stage,” fans can pay monthly pricing (billed at $3.99 on web and $4.99 in- app per month) or an annual fee of $38.30, offering VIP All-Access for the year at a 20% discount overall. As an All-Access VIP to the Fan Pass platform, fans get exclusive access to live performances and online concerts, backstage access before, during, and after the show, livestreamed studio sessions, behind-the-scenes footage of video and photoshoots, interviews and one-on-one videos, streams that highlight the daily life of their favorite artists. Additional content may be available for ticket pricing. Pricing for these tickets vary based on the event and artist. For example, K. Burns’ first livestream show cost $5.99 per ticket which is less than the amount of a ticket for an in-person venue event. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Cryptocurrencies are rapidly growing mainstream as key financial players appear ready to enter the sector
• Investors increasingly seek exposure to cryptocurrency space, but sector depends on efficient mining capacities
• ISWH ready to respond to growing market needs, partners with mining leaders to deliver top-notch solution

ISW Holdings (OTC: ISWH), a global brand-management holdings company focused on telehealth and cryptocurrency mining, appears poised to capitalize on the rapidly expanding cryptocurrency industry. The bitcoin technology market has been flourishing as cryptocurrencies continue to gain broader acceptance. Mordor Intelligence, a market research firm, valued the bitcoin tech market at more than $293.66 million in 2019, expecting it to reach $477 million by 2025 (https://ibn.fm/O8DEG). Rapidly gaining traction as acceptance of both the general and professional public grows, the sector has attracted attention from investors looking to capitalize on this burgeoning market. Once deemed an alternative, this asset is quickly moving into the mainstream. The most recent example is the investment giant JP Morgan, previously a vocal opponent to the cryptocurrency assets. The investment bank has made a radical change, embarking on the cryptocurrency journey to respond to investors’ swelling appetite for cryptocurrency exposure. According to SEC filing, the investment heavyweight has been developing a financial product based on a basket of referenced stocks of companies that own cryptocurrency or operate businesses linked to it (https://ibn.fm/aMaPX). There is no doubt that cryptocurrency is moving rapidly from investment fringes into the mainstream. To grow further, the industry relies heavily on mining hardware, which is why the sector is likely to become increasingly attractive. As a holding company committed to discovering and investing in industries that exhibit robust growth potential, ISW Holdings was quick to move into the cryptocurrency sector. Laser-focused on expanding its position in the cryptocurrency mining space, the company appears poised to capitalize on the sector’s momentum. To fully seize the emerging market opportunities, the company is committed to carefully selecting partners and teaming up with relevant players to deliver solutions that can effectively close the observed market gap. ISWH’s endeavor into the crypto-mining space was no exception. In May 2020, ISW Holdings entered into a joint venture partnership with Bit5ive to build and deliver a powerful and efficient data center pod design. Less than a year later, its revolutionary Pod5 Cryptocurrency Mining Pod was launched at the Bit5ive renewable energy cryptocurrency mining facility in Pennsylvania. Bit5ive is a company that is quickly transforming into the largest cryptocurrency mining and bitcoin farm company in the United States. Although there are many cryptocurrency mining data centers and bitcoin farms, this provider is different. Unlike traditional cloud-mining companies, where customers lease hash rate on annual contracts, Bit5ive allows ISW Holdings to own the hardware and pay monthly fees, covering costs such as electricity network, support, insurance and warranty (https://ibn.fm/xilI5). The partnership allowed ISW Holdings to design, assemble and ship its Pod5ive turnkey mining solution, which the company calls one of the most efficient data center pods in the world. The solution offers a plug-and-play technology that requires virtually no maintenance as it runs operations on a self-managed basis. Although one of the most powerful data center pods globally, it provides an industry best-in-class power usage effectiveness score. The cryptocurrency space seems to be exploding, with evidence mounting that it will continue to snowball in the time to come. The industry depends on miners and their high-performing but also cost-effective mining hardware. As a diversified portfolio company focused on essential business lines, ISW Holdings seeks to collaborate with those partners that can meet large scalability demands and effectively respond to current and anticipated marketplace needs. To deliver the most effective impact in the cryptocurrency space, the company appears adamant to move quickly and join forces with the key providers in the space. For more information, visit the company’s website at www.ISWHoldings.com. NOTE TO INVESTORS: The latest news and updates relating to ISWH are available in the company’s newsroom at http://ibn.fm/ISWH

• Researchers struggle to understand the immediate effects of COVID, with no clear census on the long-term neurological impact
• COVID-19 has shown itself to be unique in how it interacts with the brain
• Brain e-tattoos implanted in forehead will be next wave of innovation for neurology

Brain Scientific (OTCQB: BRSF) is meeting the growing need for improved brain monitoring with cost-efficient, disposable, and portable cutting-edge technology. This last year has seen an increased demand for disposable neurological technology accessible to all, adaptable for widespread use, and that provides quick, reliable information on the patient’s condition.

As the pandemic winds down, thanks to dedicated medical workers, social-distancing, mask-wearing and new vaccines, there are still many questions that need to be addressed.

The scientific world is only at the beginning of truly understanding the effects of COVID-19 on the brain. A year into the pandemic, researchers struggle to understand the immediate effects, with no clear census on the long-term impact. Neurological symptoms may go well beyond a loss of taste and smell or “brain fog” to problems with attention, concentration, and multitasking. The question is, how long will these symptoms last, and will patients eventually recover.

The Global Council on Brain Health (“GCBH”) has stated that critical research is needed in assessing how COVID-19 impacts later-in-life cognitive decline or dementia. It is not just the virus that needs to be studied, but also the impact of isolation during the pandemic on older adult brains.

COVID-19 has shown itself to be unique in how it interacts with the brain. Megakaryocytes, cells that produce platelets and primarily reside in bone marrow, have been found in the autopsied brains of COVID victims. This phenomenon has never been seen before. It may block blood flow to the brain and thereby be responsible for brain fog.

Figuring out why some patients are unaffected cognitively from COVID while others are left with significant and possibly long-term effects is essential in understanding this virus. More monitoring is needed to find the answers. That’s where Brain Scientific’s cutting-edge technology comes into play.

The NeuroEEG(TM) device is a portable, wireless, and compact device that acquires, records, transmits, and displays the wearer’s electrical brain activity. This device works in conjunction with the NeuroCap(TM), a hospital-grade disposable EEG headset featuring 19 active channels and 22 electrodes that comes in sizes for adults and pediatric patients. These devices are portable, making it simpler to take the needed tech to the patient rather than bringing the patient to the equipment.

The company is working on development of Brain E-Tattoo(TM) that in the future will provide access to long-term studies and inroads in helping identify root neurological problems. This tiny device will use graphene-based electrodes connected to the micro EEG clipped behind the ear that then transfers data to a cloud application. The data will be continuously analysed by artificial intelligence, which provides 24/7 uninterrupted monitoring.

“COVID-19 put a spotlight on the outdated and inefficient EEG testing protocols,” said Boris Goldstein, BRSF co-founder and executive. “Disposable technology made a significant impact to ensure brain scans could occur safely during the pandemic. Now, brain e-tattoos implanted in the forehead will be the next wave of innovation for neurology. The advancement will allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions. Clinicians will be able to identify brain wave activity beyond the clinical setting with no impact to the patient’s daily life.”

Thanks to cutting-edge technology such as BRSF’s NeuroCap, NeuroEEG and e-Tattoo, the answers may just lie right around the corner.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF